Research Article
A Seven-Year Retrospective Study on the Surveillance of Hepatitis B in Laos
Table 1
Type of drugs, number, and % on total and dual treatments.
| Dual therapies | Nb | % of total treatment () | % of dual therapy () |
| Cycloferon + Adefovir | 55 | 7.9% | 43.3% | Cycloferon + Lamivudine | 42 | 6.1% | 33.0% | Adefovir + Lamivudine | 9 | 1.3% | 7.1% | Cycloferon + Tenofovir | 5 | 0.7% | 4.0% | Tenofovir + Adefovir | 4 | 0.6% | 3.2% | Tenofovir + Lamivudine | 4 | 0.6% | 3.2% | Pegasys + Tenofovir | 3 | 0.4% | 2.4% | Pegasys + Adefovir | 2 | 0.3% | 1.6% | Entecavir + Tenofovir | 1 | 0.1% | 0.8% | Interferon + Cycloferon | 1 | 0.1% | 0.8% | Entecavir + Pegasys | 1 | 0.1% | 0.8% |
| Total | 126 | 18.2% | ā |
|
|